Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Jeffrey S Miller, Yvette Soignier, Angela Panoskaltsis-Mortari, Sarah A McNearney, Gong H Yun, Susan K Fautsch, David McKenna, Chap Le, Todd E Defor, Linda J Burns, Paul J Orchard, Bruce R Blazar, John E Wagner, Arne Slungaard, Daniel J Weisdorf, Ian J Okazaki, Philip B McGlave, Jeffrey S Miller, Yvette Soignier, Angela Panoskaltsis-Mortari, Sarah A McNearney, Gong H Yun, Susan K Fautsch, David McKenna, Chap Le, Todd E Defor, Linda J Burns, Paul J Orchard, Bruce R Blazar, John E Wagner, Arne Slungaard, Daniel J Weisdorf, Ian J Okazaki, Philip B McGlave
Abstract
We previously demonstrated that autologous natural killer (NK)-cell therapy after hematopoietic cell transplantation (HCT) is safe but does not provide an antitumor effect. We hypothesize that this is due to a lack of NK-cell inhibitory receptor mismatching with autologous tumor cells, which may be overcome by allogeneic NK-cell infusions. Here, we test haploidentical, related-donor NK-cell infusions in a nontransplantation setting to determine safety and in vivo NK-cell expansion. Two lower intensity outpatient immune suppressive regimens were tested: (1) low-dose cyclophosphamide and methylprednisolone and (2) fludarabine. A higher intensity inpatient regimen of high-dose cyclophosphamide and fludarabine (Hi-Cy/Flu) was tested in patients with poor-prognosis acute myeloid leukemia (AML). All patients received subcutaneous interleukin 2 (IL-2) after infusions. Patients who received lower intensity regimens showed transient persistence but no in vivo expansion of donor cells. In contrast, infusions after the more intense Hi-Cy/Flu resulted in a marked rise in endogenous IL-15, expansion of donor NK cells, and induction of complete hematologic remission in 5 of 19 poor-prognosis patients with AML. These findings suggest that haploidentical NK cells can persist and expand in vivo and may have a role in the treatment of selected malignancies used alone or as an adjunct to HCT.
Source: PubMed